RECRUITING

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Description

The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of the TG and RC in adults with elevated TG and RC.

Conditions

Hypertriglyceridemia
Talk to us

Related Conditions:

Hypertriglyceridemia

Study Overview

On this page

Study Details

Study overview

The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of the TG and RC in adults with elevated TG and RC.

Phase 2b Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of MAR001 in Patients With Elevated Triglycerides and Remnant Cholesterol (TYDAL-TIMI 78)

Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

Condition
Hypertriglyceridemia
Intervention / Treatment

-

Contacts and Locations

Mobile

Marea Site 329, Mobile, Alabama, United States, 36608

Hamden

Marea Site 306, Hamden, Connecticut, United States, 06517

Boca Raton

Marea Site 302, Boca Raton, Florida, United States, 33434

Port Saint Lucie

Marea Site 307, Port Saint Lucie, Florida, United States, 34952

Columbus

Marea Site 310, Columbus, Georgia, United States, 31904

Peachtree Corners

Marea Site 319, Peachtree Corners, Georgia, United States, 30092

Louisville

Marea Site 301, Louisville, Kentucky, United States, 40213

St Louis

Marea Site 305, St Louis, Missouri, United States, 63110

New Windsor

Marea Site 318, New Windsor, New York, United States, 12553

Greensboro

Marea Site 303, Greensboro, North Carolina, United States, 27405

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Elevated fasting TGs and RC
  • * Elevated nonfasting TGs and RC
  • * Fasting LDL-C ≥ 50 mg/dL (≥ 1.29 mmol/L) and ≤ 130 mg/dL (≤ 3.36 mmol/L)
  • * Willingness to provide informed consent and comply with the intervention and all study assessments
  • * Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study
  • * Stable drug regimen (if relevant) prior to screening visit and no planned changes during screening or trial participation
  • * Acute or chronic liver disease
  • * TG concentration ≥880mg/dl
  • * History of type 1 diabetes mellitus or history of diabetic ketoacidosis
  • * Newly diagnosed T2DM
  • * Participants with known active hepatitis A, B, or C
  • * Uncontrolled hypothyroidism
  • * Any condition that prevents the participant from complying with study procedures

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Marea Therapeutics,

Study Record Dates

2026-12